Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Update

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 2,900 shares, a decline of 29.3% from the January 31st total of 4,100 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is presently 0.7 days.

Defence Therapeutics Price Performance

Shares of OTCMKTS DTCFF remained flat at $0.79 during trading hours on Wednesday. Defence Therapeutics has a twelve month low of $0.27 and a twelve month high of $1.32. The business’s 50 day simple moving average is $0.64 and its 200-day simple moving average is $0.50.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.